Objective
Different types of tissue-associated proteases are involved in extracellularmatrix turnover in pathological conditions: 1) Matrix metalloproteases MMPs2) Cysteine proteases cathepsins B,L 3) Aspartyl protease cathepsin D4) Serine proteases plasmin and urokinase-type plasminogen activator (uPA).For invasion to take place, attachment of tumor cells to and subsequent releasefrom extracellular matrix components involving proteolysis must occur in acontrolled fashion; successful tumor cell invasion requires a balance ofproteases and protease inhibitors (limited proteolysis). Basic and clinic oriented research on tissue-associated proteases is strong in the EU member staNumerous studies on the biological and/or clinical significance of proteasestheir inhibitors and receptors under physiological and pathophysiologicalconditions have been initiated in Europe by members of this Concerted European Action: CLINICAL RELEVANCE OF PROTEASES IN TUMOR INVASION AND METASTASIS(Contract BMHl-CT93-1346; coordinator: M.Schmitt Frauenklinik TU Munchen, GermProteases and their inhibitors are of high clinical relevance for selection of high-risk groups and in predicting response to adjuvant hormone or chemotherapyThey may serve as predictive and/or prognostic factors in cancer of the breast,ovary, lung, kidney, cervix uteri and of the gastrointestinal tract. Most of thfindings, especially on uPA and cathepsin D have been made by members of thisConcerted European Action: The biological and clinical relevance of cathepsins B,L, metalloproteases and respective inhibitors in cancer progression has only recently been published. The present Concerted European Action is concerned witclinical impact of proteases and their inhibitors and receptors for prognosis(relapse-free and overall survival) and clinical decision making (adjuvant therThe very promising recent results on uPA, PAI-1, cathepsins and/or metalloproteto act as prognostic factors in cancer of the breast, ovary, stomach, colon andhave definitely stimulated eastern European partners to become a member of thisconcerted action 1) V. Turk, Ljubljana, Slovenia 2) G.Georgiev Moscow, Russia Zlatoidsky, Mostar, Slovakia 4) T.Davidenko Odessa, Ukraine 5) A.Kaban Kiev, They will be addressing the proteolytic mechanisms which underscore the invasivof tumor cells. These new activities aim at the development of novel biologicaltreatments which attenuate the invasiveness of tumor cells and may consequentlysurvival and the quality of life of patients afflicted with the disease by appltypes of agents directed to tumor-associated proteases.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Data not available
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
81675 München
Germany
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.